Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%
- Check16 days agoChange DetectedAdded a new reference for Nivolumab plus ipilimumab in advanced melanoma and updated the page version to v3.1.0; removed a closely related Genetics Information Center entry and older version, effectively replacing the reference with an updated citation. Overall, bibliographic updates with minor versioning, no other substantive content changes.SummaryDifference0.5%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1; the 'Back to Top' element has been removed.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new terms related to ovarian cancer and various chemical compounds. Notably, the previous version's references to ovarian epithelial cancer and several antineoplastic agents have been removed.SummaryDifference2%
- Check52 days agoChange DetectedThe reference to the study 'Nivolumab plus ipilimumab in advanced melanoma' has been completely removed from the page.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.